Two-in-One heart fix: bypass plus stent may beat either alone
NCT ID NCT01496664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at a 'hybrid' approach for people with severe coronary artery disease, combining bypass surgery for the main heart artery with a stent procedure for other blocked arteries. Researchers tracked 2000 patients to see if this combined treatment reduced the risk of death, stroke, heart attack, or the need for further procedures compared to using only surgery or only stents. The goal was to find a better way to manage heart disease long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2010
- Finished
-
Dec 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Stable, unstable angina pectoris and ACS. * Significant stenosis of LAD, segment 1 or 2 and of other coronary arteries. * The patient can be treated with a mammary graft to LAD and by balloon or stent of other lesions. * Signed informed consent must be available. Exclusion Criteria: * Earlier cardiac surgery * Treatment with coronary stent within one year. * ST-elevation infarction within 24 hours. * Coronary artery lesions located to LAD, segment 1 or 2, which cannot be treated by coronary bypass operation. * Stenosis of diagonal branches, CX artery and the right coronary artery, which cannot be treated by PCI. * Expected survival \<1 year following successful treatment. * Allergy to aspirin, clopidogrel, ticlopidine and/or prasugrel. * Allergy to sirolimus, everolimus, zotarolimus og biolimus For the patients treated with coronary hybrid intervention in the same seance further exclusion criteria: Known disorder of the bloods ability to coagulate (such as renal failure (dialysis or renal creatinine clearance \< 50ml/min), congenital coagulopathy, needs for anticoagulant treatment before surgery) Previous gastrointestinal bleeding or previous cerebral
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Significant coronary artery disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital, Skejby
Aarhus N, 8200, Denmark